NFKB1 and scleroderma: Nimbolide attenuated the progression of scleroderma by controlling inflammatory factors such as TNF-α, IL-1β, and p-NF-κB and by downregulating the TGF-β/Smad signaling axis (inhibition of TGF-β expression and Smad2/3 protein phosphorylation).